Candel Therapeutics Inc
Research Candel Therapeutics Inc (CADL) on Bullrun: market cap USD 756.62M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCADL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 756.62M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 38.91M
- Free cash flow-USD 17.25M
Valuation Snapshot
latest market cap is USD 756.62M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 38.18M | -USD 38.90M | n/a | -0.72 | USD 119.73M | USD 0 | USD 51.92M |
| FY2024 | USD 0 | -USD 55.18M | -USD 27.04M | n/a | -1.74 | USD 102.65M | USD 11.63M | USD 66.33M |
| FY2023 | USD 0 | -USD 37.94M | -USD 34.70M | n/a | -1.31 | USD 35.41M | USD 20.53M | USD 12.75M |
| FY2022 | USD 125.00K | -USD 18.79M | -USD 32.72M | n/a | -0.65 | USD 70.06M | USD 22.80M | USD 47.71M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 756.62M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 310.18M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 406.32M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 42.51M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 51.72M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 224.35M | n/a | n/a | n/a |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Candel Therapeutics Inc's market cap?
Candel Therapeutics Inc's market capitalization is USD 756.62M.
What does Candel Therapeutics Inc do?
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.